Search Within

Andrew D Seidman

  1. "Elsevier Inc."
Formats
  1. Journal Article (40)
  2. Meeting Abstract (9)
  3. Conference Paper (4)
  4. Research Letter (1)
  5. Review (1)
Groups
  1. Breast Medicine Service (55)
  2. Department of Medicine (55)
  3. Solid Tumor Oncology Division (55)
  4. Survivorship Research (29)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (21)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Clifford Hudis (17)
  2. Larry Norton (14)
  3. Jonathan Yang (7)
  4. Shanu Modi (7)
  5. Zhigang Zhang (7)
  6. Gabriella D'Andrea-Carlino (6)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2022 (2)
  5. 2021 (2)
  6. 2018 (4)

More Years

Publications
  1. Clinical Breast Cancer (19)
  2. Seminars in Oncology (16)
  3. International Journal of Radiation Oncology, Biology, Physics (8)
  4. European Journal of Cancer (4)
  5. Breast (2)
  6. Breast Diseases: A Year Book Quarterly (2)

More Publications

Publishers
  1. Elsevier Inc. (55)

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: Focus on cardiac safety
    Journal Article

    Seidman, A. D.
    Breast Diseases: A Year Book Quarterly (2005)

    Fulltext@MSK | Save
  • A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Journal Article

    Modi, S.; Currie, V. E.; Seidman, A. D.; Bach, A. M.; Panageas, K. S.; Theodoulou, M.; Moasser, M. M.; D'Andrea, G. M.; Lake, D. E.; Choi, J.; more...
    Clinical Breast Cancer (2005)

    Fulltext@MSK | Save
  • Single-agent gemcitabine in the treatment of advanced breast cancer
    Journal Article

    Modi, S.; Seidman, A. D.
    Clinical Breast Cancer (2004)

    Fulltext@MSK | Save
  • Effect of cardiac dysfunction of treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer
    Journal Article

    Tripathy, D.; Seidman, A.; Keefe, D.; Hudis, C.; Paton, V.; Lieberman, G.
    Clinical Breast Cancer (2004)

    Fulltext@MSK | Save
  • HER2-overexpressing metastatic breast cancer: The role of trastuzumab regimens
    Journal Article

    Danso, M. A.; Seidman, A. D.
    Clinical Breast Cancer (2003)

    Fulltext@MSK | Save
  • Monotherapy options in the management of metastatic breast cancer
    Journal Article

    Seidman, A. D.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save
  • Cardiac effects of adjuvant therapy for early breast cancer
    Journal Article

    Theodoulou, M.; Seidman, A. D.
    Seminars in Oncology (2003)

    Fulltext@MSK | Save
  • Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer
    Journal Article

    Dang, C.; Seidman, A. D.
    Cancer Treatment Reviews (2003)

    Fulltext@MSK | Save
  • Commentary on "HER2/neu as a predictive factor in breast cancer"
    Journal Article

    Van Poznak, C.; Seidman, A. D.
    Clinical Breast Cancer (2001)

    Fulltext@MSK | Save
  • Weekly (W) herceptin (H) and taxol (T) for metastatic breast cancer (MBC): Correlation of response rate to HER2 immunophenotype (immunohistochemistry (IHC)) and gene amplification (fluorescent in-situ hybridization (FISH))
    Meeting Abstract

    Fornier, M.; Seidman, A. D.; Esteva, F.; Tan, L.; Kaptain, S.; Bach, A.; Arroyo, C. D.; Hortobagyi, G.; Norton, L.; Hudis, C.
    European Journal of Cancer (2000)

    Fulltext@MSK | Save